ArticleClinical epigenetics2026
Genebody specific epigenomic reprogramming of transcriptome promotes immune evasion in oropharyngeal cancer patients in North-Eastern India.
Article in Clinical epigenetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundSquamous cell carcinoma of oropharynx (OPSCC), a head and neck squamous cell carcinoma (HNSCC) subtype, exhibits a remarkably high incidence rate in the North-Eastern regions of India. The development of OPSCC is associated with the exposure to smokeless tobacco with or without consumption of alcohol and smoking tobacco. Despite advanced treatment modalities, OPSCC patients still face a dismal prognosis, necessitating a deeper exploration of the underlying molecular characteristics of the disease. While promoter CpG methylation-driven gene expression alterations in OPSCC have been studied, DNA methylation within gene bodies and its biological significance in this cancer subtype remain largely uncharted. This study represents the first endeavour to investigate gene-body specific DNA methylation-driven transcriptome alterations leading to immune response modulation on a genome-wide scale in OPSCC.
resultsThe genome-wide assay of DNA methylation and RNA-sequencing in paired tumour and adjacent normal tissues, employing high-throughput platforms (Illumina), identified gene-body specific somatic alterations within the DNA methylome that led to transcriptomic changes in OPSCC patients from Meghalaya. Integrative analysis of gene-body specific methylation and transcriptome data unveiled 98 epigenetically repressed and 39 epigenetically overexpressed genes. Major discoveries emerged from this study include deregulation of Tryptophan (Trp) metabolism pathway by the gene-body driven epigenetically modulated (TDO2, KYNU and TPH2) genes along with the conjoint impact of the upregulated IDO1, IDO2. The IFN-γ mediated PD-L1/PD-1, PD-L2/PD-1 interactions and dysregulation of Trp metabolism pathway collectively contributed to the depletion of cytotoxic T cells in OPSCC tissues. Upregulation of multiple chemokines-CCL2, CXCL1, CXCL2 promoting abundant infiltration of mast cell and neutrophils having pro-tumour phenotype in tumour microenvironment were observed.
conclusionsThese key alterations within tumour cells might effectively modulate the immune dynamics, leading to immune evasion by oropharyngeal malignant cells. The findings offer deep understanding of OPSCC and suggests novel immunotherapeutic targets, for the treatment of this challenging disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.